FUSION HEALTH CARE

What FUSION HEALTH CARE does

Fusion Health Care is an Indian pharmaceutical company founded in 2007 and headquartered at Fusion House, Banjara Hills, Hyderabad. The company operates as an integrated pharmaceutical organization combining research, manufacturing, and marketing under founder and Managing Director Madhu Ramadugu, with a nationwide direct-sales presence in India and an export operation serving international markets. Its therapeutic focus is split between Anti-Infectives/Critical Care (marketed in part under the Klinikos brand) and Cardio-Metabolics, serving doctors, hospitals, and healthcare institutions that treat critically ill patients and patients with cardiac and metabolic disorders.

The company's manufacturing footprint is anchored by WHO-GMP approved API plants producing Glimepiride, Montelukast, Rivaroxaban, and Dapagliflozin; WHO-GMP, EU-GMP, and USFDA compliant injectable facilities for sterile formulations; and WHO-GMP and FDA-Philippines approved oral formulation facilities. A dedicated R&D facility in Hyderabad houses 20 scientists supporting end-to-end capabilities from formulation research and pilot batches through large-scale manufacturing and distribution. The combined effect is a vertically integrated operation spanning molecules, manufacturing formats, and therapy areas, with multiple regulatory clearances that qualify products for both domestic and select regulated export markets.

Fusion Health Care generates revenue through direct sales of pharmaceutical products to healthcare professionals and institutions across India, supplemented by an International Business vertical that handles enquiries, packing, shipments, and competitive pricing for export customers. The go-to-market relies on direct field sales supplemented by academic engagement at major Indian and international conferences in critical care, cardio-diabetes, and general specialties, with downloadable cardio-metabolics and anti-infectives product portfolios used as mid-funnel physician tools. The company is privately held, founder-led, and discloses no venture capital, private equity, or parent-company relationships, with no publicly available revenue or funding figures.

Name

FUSION HEALTH CARE

Legal name

Fusion Healthcare

Website

https://fusionhealthc.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

Fusion Health Care is a Hyderabad-based, privately held Indian pharmaceutical company founded in 2007 that researches, manufactures, and markets APIs, injectables, and oral formulations for healthcare professionals, hospitals, and international buyers across anti-infectives/critical care and cardio-metabolics.

Ownership category

akta.pro rank

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Manufacturing: Manufacturing revenue from WHO-GMP, EU-GMP, and USFDA compliant pharmaceutical manufacturing including injectables and oral formulations
2. Active Pharmaceutical Ingredients (API): Sale of APIs including Glimepiride, Montelukast, Rivaroxaban, and Dapagliflozin
3. International Business: Export services including enquiries handling, packing, shipments, and competitive pricing for international markets

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Fusion Health Care is an Indian pharmaceutical company that manufactures and markets Active Pharmaceutical Ingredients (APIs) such as Glimepiride, Montelukast, Rivaroxaban, and Dapagliflozin, along with sterile injectables and oral formulations in WHO-GMP, EU-GMP, USFDA, and FDA-Philippines approved facilities. Its therapeutic focus spans anti-infectives/critical care and cardio-metabolics, with products sold to healthcare professionals, hospitals, and international distributors.

Product overview

Fusion Healthcare is an Indian pharmaceutical company founded in 2007, operating as a fully integrated pharmaceutical organization with research, manufacturing, and marketing capabilities. The company offers a diversified portfolio organized across three main business verticals: API (Active Pharmaceutical Ingredients) covering WHO-GMP approved molecules including Glimepiride, Montelukast, Rivaroxaban, and Dapagliflozin; Formulation products spanning Injectables (WHO-GMP, EU-GMP, USFDA compliant) and Orals (WHO-GMP, FDA-Philippines approved); and International Business for global export services. The therapeutic focus areas include Anti-Infectives/Critical Care as a flagship division providing innovative critical care products for critically ill patients, and Cardio-Metabolics offering branded generic molecules for cardiac and metabolic disorders. Manufacturing capabilities are anchored by cutting-edge facilities in Hyderabad with a state-of-the-art R&D center employing 20 scientists, supported by over 500 total employees.

Differentiator

Problem solved

Functional benefit

Brands

• Klinikos: Product portfolio brand for anti-infectives/critical care products
• Fusion House

Products and services

• Active Pharmaceutical Ingredients (API) WHO-GMP approved active pharmaceutical ingredients including Glimepiride, Montelukast, Rivaroxaban, and Dapagliflozin, sold to pharmaceutical manufacturers and formulation companies.
• Injectables Sterile pharmaceutical injectable formulations manufactured in WHO-GMP, EU-GMP, and USFDA compliant facilities, supplied to hospitals and healthcare institutions.
• Orals Oral solid dosage pharmaceutical formulations manufactured in WHO-GMP and FDA-Philippines approved facilities for cardiac and metabolic therapeutic segments.
• Cardiology Products Branded generic molecules for treating cardiac disorders and their comorbidities, supplied to healthcare professionals and institutions.
• Metabolics Products Branded generic molecules for treating metabolic disorders and their comorbidities, supplied to healthcare professionals and institutions.
• Anti-Infectives / Critical Care Critical care pharmaceutical products including the FHC Product Portfolio and Klinikos Product Portfolio for treating critically ill patients in hospital and intensive care settings.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Cipla: Larger Indian pharmaceutical incumbent with broad therapeutic portfolio including injectables and APIs. Overlaps with Fusion Healthcare in critical care and cardio-metabolic therapies, but operates at a much larger scale with diversified portfolio.
• Dr. Reddy's Laboratories: Larger diversified Indian pharma with global generics, APIs, and biosimilars. Overlapping capabilities in sterile injectables and cardio-metabolic molecules, but with significantly broader portfolio and global footprint.

Direct peers

• Strides Pharma: Indian injectable-focused specialty manufacturer with regulated-market approvals (USFDA, EU-GMP). Highly comparable in targeting sterile injectables as a flagship vertical alongside oral solids.
• Natco Pharma: Indian pharma focused on branded generics and complex generics with API capabilities. Comparable therapeutic focus and regulatory strategy across multiple jurisdictions.
• Aurobindo Pharma: Large Indian generic and API manufacturer with strong injectable and oral formulation capabilities across cardio-metabolic and anti-infective therapies. Closely comparable vertically integrated model targeting USFDA- and EU-GMP-approved markets.
• Lupin: Indian major with API plus complex generics including injectables and orals across cardio-metabolic and anti-infective areas. Comparable mix of regulated-market certifications and India-domestic branded generics.
• Emcure Pharmaceuticals: Indian pharmaceutical company with strong injectables, oral solids, and API presence with international exports. Comparable business mix across critical care and chronic therapy segments.
• Cadila Healthcare (Zydus): Integrated Indian pharma with API, formulations, and biologics. Comparable vertically integrated model with similar therapeutic portfolio across cardio-metabolic and anti-infective areas.
• Alkem Laboratories: Indian pharmaceutical manufacturer with API and finished formulations across anti-infectives and chronic therapies. Comparable business mix and regulatory footprint across multiple geographies.
• Torrent Pharmaceuticals: Indian pharma with formulations spanning cardio-metabolic and other chronic areas plus international presence. Comparable domestic-international split and branded generics orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/fusionhealthcr
• LinkedInlinkedin.com/company/fusion-health-care-pvt-ltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FUSION HEALTH CARE